Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024

 Laxxon Medical, a US-based pharma-technology company pioneering a new generation of advanced pharmaceuticals through novel 3D screen-printing platform technology SPID®, announced today its participation in the 2024 BIO International Convention on June 3-6, 2024 in San Diego, CA. The Company will be showcasing its LXM.2 asset to potential partners.

Visit here for more details: https://www.laxxonmedical.com/post/laxxon-medical-to-showcase-lxm-2-a-novel-3d-printed-glp-1-agonist-at-bio-2024

Comments

Popular posts from this blog

Drug Patents and Drug Exclusivity

Uncovering the Power of Google Sites Alt Text for SEO

The Impact of Water Filtration Systems on Family Health: Safeguarding All Generations